Recent 2022 SARS-CoV-2 Omicron variants, have acquired resistance to most neutralizing
anti-Spike monoclonal antibodies authorized, and the BQ. 1.* sublineages are notably …

The treatment for COVID-19 has evolved rapidly since the start of the pandemic and now
consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir …

Background: While passive immunotherapy has been considered beneficial for patients with
severe respiratory viral infections, the treatment of COVID-19 cases with convalescent …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Background Convalescent plasma (CP) transfusion is an early option for treating infections
with pandemic potential, often preceding vaccine or antiviral drug rollout. Heterogenous …

Objectives Immunocompromised patients have an increased risk of severe or prolonged
COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 to 7 …

Background Effective antiviral drugs accelerate viral clearance in acute COVID-19
infections; the relationship between accelerating viral clearance and reducing severe …

Background During pandemics, early outpatient treatments reduce the health system
burden. Randomized controlled trials (RCTs) in COVID-19 outpatients have tested …

Multiple randomized, controlled clinical trials have yielded discordant results regarding the
efficacy of convalescent plasma in outpatients, with some showing an approximately 2-fold …